SGS expands elemental impurity testing services
![](/46/pdcnewsitem/07/54/87/acid-biology-chemical-1366944.jpg)
Company has successfully developed and validated impurity test methods in line with ICH Q3D regulatory guidelines.
SGS has expanded elemental analysis testing capabilities at its Chennai, India laboratory. The site has invested in three inductively coupled plasma mass spectrometry (ICP-MS) systems, in a move to address the updated ICH Q3D regulatory guidelines on elemental impurities and establish a South East Asia Center of Excellence for elemental analysis.
ICH Q3D Step 4 was published in December 2014. Since then, it has required that a risk analysis be deployed for all drug products on the specified list of elements and their permitted daily exposure (PDE) limits. The guideline came into effect in June 2016 for new drug products, and existing products needed to comply by December 2017. Using Agilent 7700 and 7800 ICP-MS systems, SGS’s laboratory in Chennai has now successfully developed and validated impurity test methods in line with ICH Q3D.
Chennai now joins a number of the laboratories across Europe and North America within the SGS laboratory network to offer elemental impurity testing for pharmaceutical products, and providing local support to drug developers.
“SGS has a well-trained and qualified elemental impurities team in Chennai that can effectively support pharmaceutical and biopharmaceutical companies in the South East Asia region, in accordance with the ICH 3QD guidelines,” commented Sathananthan Sangaran, National Operations Director of India. He added: “On a global level, SGS is fully committed to offering its clients access to the very latest technology and expertise to ensure regulatory demands can be met efficiently.”
The 1,850-m2 Chennai laboratory was opened in 2005 and has strong capabilities in method development and validation analytical chemistry as well as batch release, utilities qualification and monitoring; healthcare product and healthcare supplement testing; microbiological testing; safety and stability studies.
![SGS](https://www.cphi-online.com/th247924-comp247924.png)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance